Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morphine for Dyspnea and Cough in Fibrotic Interstitial Lung Disease
2023-503700-81-00Phase 4Authorised
- Sponsor
- Aarhus University Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Metformin glycinate and morphine in pulmonary fibrosis (PF) (2 arms), sponsored by Aarhus University Hospital. Primary endpoint: Change in average VAS dyspnea score over 24 hours. Planned start Mar 2024; status: authorised.
02
Drugs
Metformin glycinatemorphine
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on 2023-503700-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503700-81-00.